九价人乳头瘤病毒疫苗接种后抗体阳转率的meta分析

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (1179 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the rate of antibody positive conversion after 9-valent human papillomavirus(HPV) vaccination by meta-analysis. Methods Randomized controlled trials (RCT) were searched in PubMed, Embase,CNKI, Wanfang and VIP databases for the positive rate of antibody after vaccination with 9-valent HPV vaccine and with quadrivalent HPV vaccine until November 2021. Meta-analysis was performed using Stata 12.0 software. Results A total of 6 RCTs were included. The results showed that there was no statistically significant difference in anti-HPV-6/11/16/18 positive rate between 9-valent HPV vaccine and quadrivalent HPV vaccine after inoculation (P>0.05). The positive rates of anti-HPV-31/33/45/52/58 with nine-valent HPV vaccine were higher than those of quadrivalent HPV vaccine, and the differences were statistically significant (anti-HPV-31: RR=2.10, 95%CI=1.86-2.36; anti-HPV-33:RR-7.99, 95%CI=7.01-9.11; anti-HPV-45: RR=11.03, 95%CI=9.21-13.20; anti-HPV-52: RR=32.17, 95%CI=26.51-39.05; anti-HPV-58: RR=4.96, 95%CI=3.91-6.28). Conclusion Compared with quadrivalent HPV vaccine, nine-valent HPV vaccine has good immunogenicity.

Key words： Human papillomavirus Randomized controlled trials Antibody positive rate Meta analysis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Chengfeng
	DONG Yonghai
	LIU Yun
	YANG Cheng

Cite this article:

ZHANG Chengfeng,DONG Yonghai,LIU Yun, et al. A meta-analysis of antibody positive rate after nine-valent HPV vaccination[J]. 中国当代医药, 2022, 29(27): 10-14.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I27/10

[1]	Roman BR，Aragones A.Epidemiology and incidence of HPVrelated cancers of the head and neck[J].J Surg Oncol，2021，124（6）：920-922.
[2]	Scott-Wittenborn N，Fakhry C.Epidemiology of HPV Related Malignancies[J].Semin Radiat Oncol，2021，31（4）：286-296.
[3]	Quinlan JD.Human Papillomavirus：Screening，Testing，and Prevention[J].Am Fam Physician，2021，104（2）：152-159.
[4]	Salvadori MI.Human papillomavirus vaccine for children and adolescents[J].Paediatr Child Health，2018，23（4）：262-265.
[5]	Wnukowski-Mtonga P，Jayasinghe S，Chiu C，et al.Scientific evidence supporting recommendations on the use of the 9-valent HPV vaccine in a 2-dose vaccine schedule in Australia[J].Commun Dis Intell （2018），2020：44.
[6]	Olsson SE，Restrepo JA，Reina JC，et al.Long -term immunogenicity，effectiveness，and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age：Interim analysis after 8 years of follow-up[J].Papillomavirus Res，2020，10：100 203.
[7]	Du J，ahrlund-Richter A，Nasman A，et al.Human papilloma virus （HPV） prevalence upon HPV vaccination in Swedish youth：a review based on our findings 2008-2018，and perspectives on cancer prevention[J].Arch Gynecol Obstet，2021，303（2）：329-335.
[8]	Garland SM，Pitisuttithum P，Ngan H，et al.Efficacy，Immunogenicity，and Safety of a 9-Valent Human Papillomavirus Vaccine：Subgroup Analysis of Participants From Asian Countries[J].J Infect Dis，2018，218（1）：95-108.
[9]	Ruiz-Sternberg áM，Moreira EJ，Restrepo JA，et al.Efficacy，immunogenicity，and safety of a 9-valent human papillomavirus vaccine in Latin American girls，boys，and young women[J].Papillomavirus Res，2018，5：63-74.
[10]	Van Damme P，Meijer C，Kieninger D，et al.A phase Ⅲclinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men[J].Vaccine，2016，34（35）：4205-4212.
[11]	Joura EA，Giuliano AR，Iversen OE，et al.A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women[J].N Engl J Med，2015，372（8）：711-723.
[12]	Garland SM，Cheung TH，Mcneill S，et al.Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine[J].Vaccine，2015，33（48）：6855-6864.
[13]	Vesikari T，Brodszki N，van Damme P，et al.A Randomized，Double-Blind，Phase ⅢStudy of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine （V503） Versus Gardasil? in 9-15-Year-Old Girls[J].Pediatr Infect Dis J，2015，34（9）：992-998.
[14]	郑子培，贾钰琳，欧阳国莲.天津市社区18～65 周岁女性对宫颈癌筛查和HPV 疫苗认知调查[J].中国卫生产业，2019，16（30）：180-182.
[15]	陈琳，张慧，田晋莹，等.广东省某医药院校大学生人乳头瘤病毒疫苗接种意愿调查[J].现代预防医学，2020，47（5）：917-921.
[16]	李欣怡，许亚萌，宋雨，等.石家庄市大学生对HPV 认知状况及疫苗接种意愿调查[J].河北医科大学学报，2021，42（8）：944-949.
[17]	Yang DY，Bracken K.Update on the new 9-valent vaccine for human papillomavirus prevention [J].Can Fam Physician，2016，62（5）：399-402.
[18]	Signorelli C，Odone A，Ciorba V，et al.Human papillomavirus 9-valent vaccine for cancer prevention：a systematic review of the available evidence[J].Epidemiol Infect，2017，145（10）：1962-1982.
[19]	Costa A，Cobucci R，Da SJ，et al.Safety of Human Papillomavirus 9-Valent Vaccine：A meta-Analysis of Randomized Trials[J].J Immunol Res，2017，2017：3 736 201.
[20]	张继红，腾国伟，斗智，等.九价人乳头瘤病毒疫苗接种后保护效果、免疫原性及安全性meta 分析[J].中国公共卫生，2019，35（4）：491-496.
[21]	Huh WK，Joura EA，Giuliano AR，et al.Final efficacy，immunogenicity，and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years：a randomised，double-blind trial[J].Lancet，2017，390（10 108）：2143-2159.
[22]	Guevara A，Cabello R，Woelber L，et al.Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine[J].Vaccine，2017，35（37）：5050-5057.